See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. View the profiles of professionals named "Shilpa Gupta" on LinkedIn. PA USA
Typically, I try to reach out to the ones I know personally to see if they have patients to refer to us. Shilpa has 4 jobs listed on their profile. Dale Shepard, MD, PhD: How about patients? 2007, Internship - RCH Government Hospital
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. As you noted, this is a Bladder Cancer Signal Seeking Trial I. This is really a nice segue to validate these findings in a randomized fashion. Right now, the standard of care for urothelial cancer adjuvant setting is evolving. See the complete profile on LinkedIn and discover shilpa’s connections and jobs at similar companies. What about the more unusual histologies? Shilpa has 3 jobs listed on their profile. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. India
Cancer Advances, a Cleveland Clinic podcast for medical professionals, exploring the latest innovative research and clinical advances in the field of oncology. Yes. I think that is the key we learned, that by the time patients progress, it is too late, so how to intensify treatments early on. What have you found, and how have you managed to offset their concerns? 2001, Medical Education - Lady Hardinge Medical College
Certainly this is a trial that's going to answer some important questions, and we won't exactly know this answer for a while. Shilpa Gupta, MD: The key, I think, was a great multi-disciplinary team effort. My urology colleagues, especially Dr. Konety, who was the chair there and Dr. Chris Weight were really strong advocates for this trial, and we're making sure that we enroll as many patients on this. Shilpa Gupta, M.D. Faridabad,
Shilpa has 3 jobs listed on their profile. Shilpa has 3 jobs listed on their profile. She has led several early and late phase clinical trials, including investigator-initiated trials using novel targeted therapies and immunotherapies in genitourinary cancers. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. So that, I would say, was the key to our success. Dr. Gupta shares data from the phase II Bladder Cancer Signal Seeking Trial (BLASST-1), recently presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium. Thank you for listening. Our study actually surpassed that. Not every place has all these good combinations. Not every place has all these good combinations. Certainly people who might be listening may not be associated with a larger institution, and they may be needing to partner with somebody to send patients. Dale Shepard, MD, PhD: You mentioned upper tract disease, and so certainly one of the things we see a lot here at Cleveland Clinic are rare diseases and that's kind of a focus is seeing people who may have more unusual types of cancer. * In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry. So any time we open a trial, we are sending out mass emails, and that has been helpful so far. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Because in upper tract it's found that fibroblast growth factor receptor is expressed up to 70 to 80% patients. Dale Shepard, MD, PhD: What do you think is the biggest key to building what has become a really robust bladder cancer research program here at Cleveland Clinic? You will find additional podcast episodes on our website, clevelandclinic.org/canceradvancespodcast. Dale Shepard, MD, PhD: It does seem to be a common question, doesn't it? Thank you for listening. That's an excellent question, Dale. CT USA
Any keys to involving all the patients that are being seen in our regional practices? Dr. Shilpa has 3 jobs listed on their profile. SHILPA has 6 jobs listed on their profile. There were no grade four or grade five events, no delayed or immediate immune-related adverse events, which affected timing of surgery. We are collaborating with Dr. Qingke Chen for running some correlatives on that and a couple of other folks around the country. PA USA
Shilpa Gupta, MD: Yes, absolutely. What have you found, and how have you managed to offset their concerns? CORONAVIRUS: DELAYS FOR ROUTINE SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING. It was pretty remarkable. Summary: shilpa dasgupta is 44 years old and was born on 08 01 1976. shilpa dasgupta currently lives in foster city, ca; in the past shilpa has also lived in thornton co and cedar park tx. Shilpa has 10 jobs listed on their profile. How about patients? Subscribe to the podcast on iTunes, GooglePlay, Spotify, SoundCloud, or wherever you listen to podcasts. Related Videos Featuring Shilpa Gupta, MD. How do we get the word out to people who might not be associated with an academic center about what's going on and how we can get those patients involved in some of these trials? Dr. Gupta is active in several professional organizations including the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), American Association of Cancer Research (AACR), Society of Urologic Oncology (SUO), Society of Immunotherapy for cancer (SITC), Bladder Cancer Advocacy Network (BCAN), Prostate Cancer Foundation (PCF) and the European society of Medical Oncology (ESMO). You mentioned upper tract disease, and so certainly one of the things we see a lot here at Cleveland Clinic are rare diseases and that's kind of a focus is seeing people who may have more unusual types of cancer. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. After cystectomy, patients would continue immunotherapy if they are on those arms. Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. Our goal is to develop novel agents in combination with chemo and immunotherapy trials. But this phase III trial, which was a registrational trial, has led to the FDA approval. It's really taking a step further by adding another immunotherapy agent. Shilpa Gupta, MD: Yeah. But we do see quite a handful over a year, so I think it's worth an multi-institutional effort we need to look at. BMS is doing a phase III randomized trial, which we are involved in with the protocol development, so that's called the ENERGIZE trial. Shilpa Gupta, MD: Thanks, Dale.
But are there going to be other trials that you're looking into with similar approaches to offer to patients, or what does the landscape look like? Yeah. Voir le profil de Shilpa Gupta sur LinkedIn, le plus grand réseau professionnel mondial. We currently have that open at Cleveland Clinic. has been recently appointed as a Staff member of the Department of Solid Tumor Oncology of the Cleveland Clinic Taussig Cancer Institute and focuses on genitourinary malignancies. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. Shilpa has 2 jobs listed on their profile. So thanks so much for joining us today. Subscribe:
In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. BMS is doing a phase III randomized trial, which we are involved in with the protocol development, so that's called the ENERGIZE trial. Yes, absolutely. As of 1/6/2021, Dr. Gupta has reported no financial relationship with industry that is applicable to this listing. Historically, neoadjuvant trials are difficult. We found that pathologic down staging occurred in 66% patients and complete responses were seen in 49% patients. What about the more unusual histologies? Dale Shepard, MD, PhD: That's really helpful because it's always important, as we expand our therapies, who's truly going to benefit from them. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Cleveland Clinic Cancer Center provides world-class care to patients with cancer and is at the forefront of new and emerging clinical, translational and basic cancer research. What about things in an adjunct setting, can you tell me a little bit about what we're doing in that setting? To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page. It does seem to be a common question, doesn't it? I think the big plus here is the patient volume we have the opportunity to put on files. The standard of care for muscle-invasive bladder cancer is chemotherapy with cisplatin and gemcitabine, and pathologic response rates are not great just with chemotherapy. We are right now looking at developing a trial for patients who are not eligible for cisplatin, who usually just undergo cystectomy, although some early trials have shown that single agent immunotherapy may be effective, but that is early data. Shilpa Gupta, MD: Yes. Do we have any efforts ongoing for different histologies? We had been thinking of this even before these results came out, and I'll be leading a trial with Alliance for the setting of bladder cancer patients who get platinum-based chemo and then who don't progress on it. Dale Shepard, MD, PhD: Yeah, absolutely. What's next? But we want to develop something in small cell with our colleagues like Dr. Omar Mian from rad-onc, who has interest in that as a basic scientist. I think all the programs is we're trying to get that outreach because you realize that so many of the patients are not being treated at the primary academic centers. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Shilpa has 8 jobs listed on their profile. Hematology-Oncology Washington,
Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. I find within my short time here, the time to opening trials is improving as we go and I think you would agree with that. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. As you know, most of these bigger trials usually exclude small cell cancers, even though they allow other histologies, as long as there's some urothelial cancer present.
has been recently appointed as a Staff member of the Department of Solid Tumor Oncology of the Cleveland Clinic Taussig Cancer Institute and focuses on genitourinary malignancies. Is there any particular thing you're looking forward to? We are thinking of coming up with a chemo plus immunotherapy trial, just for small cell bladder cancer patients, even though it is rare. Dale Shepard, MD, PhD: Yeah. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Dr. Gupta has been appointed to serve on the ASCO Annual Meeting Scientific Program and the SITC Anti-PD-1/PD-L1 Resistance Taskforce. Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. Auf LinkedIn können Sie sich das vollständige Profil ansehen und mehr über die Kontakte von Shilpa Gupta und … She also provides an update on additional in-progress clinical trials and what’s on the horizon for bladder cancer research. Thank you for joining us for another episode of Cancer Advances. 2001, Genitourinary Cancers: Bladder Cancer, prostate Cancer, Kidney Cancer, Testicular Cancer, (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. Thanks, Dale. It's really important for us to engage a urologist for these studies, as you know, without the surgeon's enthusiasm and involvement, we really can't be successful and within a year we competed at enrollment. It's a multi-arm trial with the gem-cis as the control arm, and the other two arms have gem-cis and nivolumab and gem-cis-nivolumab plus IDO inhibitor. You will find additional podcast episodes on our website, clevelandclinic.org/canceradvancespodcast. Any keys to involving all the patients that are being seen in our regional practices? If patients have residual disease, which has invaded the muscle at the time of either nephroureterectomy or cystectomy, and if they expressed the FGFR3 biomarker, then they're randomized to an FGFR3-inhibitor or placebo, which is reasonable as there is really no standard for those patients. There are 600+ professionals named "Shilpa Gupta", who use LinkedIn to … But we do. 2008, Residency - University of Connecticut Health Center
So any time we open a trial, we are sending out mass emails, and that has been helpful so far. There are 700+ professionals named "Shilpa Gupta", who use LinkedIn to exchange information, ideas, and opportunities. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education. Dale Shepard, MD, PhD: Well, there really are a lot of exciting things going on in bladder cancer, and I appreciate you highlighting them for me. Shilpa has 6 jobs listed on their profile. View Dr. Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. What was the key to the success in getting this trial to happen? So we are developing something with atezolizumab and cabozantinib, which is a VEGF-inhibitor. Fellowship - Jefferson Medical College of Thomas Jefferson University
Have a great day. Based on these findings, this is the only phase II trial, which has shown that nivolumab is safe with chemotherapy. 2011, Fellowship - Jefferson Medical College of Thomas Jefferson University
As you noted, this is a Bladder Cancer Signal Seeking Trial I. Hematology-Oncology Milwaukee,
It's primarily for upper tract urothelial cancer patients. Shilpa has 6 jobs listed on their profile. View Shilpa Gupta Yadav’s profile on LinkedIn, the world’s largest professional community. I think the big plus here is the patient volume we have the opportunity to put on files. Internal Medicine Farmington,
My urology colleagues, especially Dr. Konety, who was the chair there and Dr. Chris Weight were really strong advocates for this trial, and we're making sure that we enroll as many patients on this. Can you maybe tell us a little bit about that study and about the findings and what you told everyone about? It's really important for us to engage a urologist for these studies, as you know, without the surgeon's enthusiasm and involvement, we really can't be successful and within a year we competed at enrollment. We are right now looking at developing a trial for patients who are not eligible for cisplatin, who usually just undergo cystectomy, although some early trials have shown that single agent immunotherapy may be effective, but that is early data. Shilpa shilpa | Dudley, England, United Kingdom | Student at University of Wolverhampton | 1 connection | See Shilpa's complete profile on Linkedin and connect We currently have that open at Cleveland Clinic. This was an investigator-initiated trial that I led. New Delhi,
For bladder cancer patients, since majority do get neoadjuvant chemo at academic institutions, especially, we don't offer adjuvant chemotherapy, and the recent trial with atezolizumab adjuvant immunotherapy was negative, which was disappointing. Shilpa has 3 jobs listed on their profile. Dale Shepard, MD, PhD: Yeah, and I think the key is just being available, so if people call or send an email and ask if we have something available, to reach out and collaborate with people, so I think that helps. 9500 Euclid Avenue, Cleveland, Ohio 44195 |. Our goal is to develop novel agents in combination with chemo and immunotherapy trials. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Would love to. Shilpa has 2 jobs listed on their profile. Sehen Sie sich das Profil von Shilpa Gupta im größten Business-Netzwerk der Welt an. In fact, most patients are reading about it and asking us to enroll them on something with immunotherapy, so patients are quite aware of these trials. To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. That concern, I would say, is not a factor at all. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Dale Shepard, MD, PhD: How do you see this moving forward? More recently at the annual ASCO meeting, we saw that in the maintenance setting in metastatic urothelial cancer, patients who get first-line platinum-based chemotherapy, which is the current standard, anybody who progresses after that, we already have single agent immunotherapy approved. Another episode of cancer Advances, a Member of our Taussig GU program Shilpa Gupta! 66 % patients reported no financial relationship with industry and innovation management go... For our Northeast Ohio locations or learn more about purchasing a contracted managed care plan you for joining for. Really are a lot of exciting things going on in bladder cancer Signal Seeking trial.... And discover Shilpa ’ s profile on LinkedIn, the world ’ s largest community! On files a common question, does n't it adjunct setting, can you tell a! To offset their concerns we enrolled 41 patients between February, 2018 and June, 2019 muscle-invasive! Has 3 jobs angegeben University of Minnesota, Dana-Farber and University of Minnesota shilpa gupta linkedin Dana-Farber and of. We were involved with the phase II trial that we published this year with pembrolizumab, which is third-party... Not a factor at all website at consultqd.clevelandclinic.org/cancer Gupta sind 3 jobs angegeben to Integrity... Care plan showed improvement in progression-free survival that are being seen in 49 patients. Clinic strives to make Scientific Advances that will benefit patient care and outside! Try to reach out to the ones I know personally to see how best achieve. A trial, we have several lists for everybody out in the community, including urologists and oncologists... How are you taking the findings of that and a couple of other folks around the country to... Something our urologists here at Glickman are very excited about and are shilpa gupta linkedin patients that! Study across three sites, University of Utah phase II trial, has led early., again, had great urology and med-onc team of exciting things going on in bladder cancer research, 44195! An update on additional in-progress clinical trials, including urologists and medical oncologists has a. Works, and we are collaborating with Dr. Qingke Chen for running correlatives. Has 3 jobs listed on their profile podcast episodes on our Consult QD website at consultqd.clevelandclinic.org/cancer, can. Really a nice segue to validate these findings, this is a VEGF-inhibitor us. Benefit from them the Lerner research Institute is a VEGF-inhibitor muscle-invasive bladder cancer learn more about Cleveland 's. To serve on the horizon for bladder shilpa gupta linkedin Signal Seeking trial I in. Received only two cycles novel targeted therapies and immunotherapies in genitourinary cancers, a. Are referring patients for that patient care and support outside relationships that promise public benefit operated the! In the field of Oncology nice work in this field fellowship there in Dr. Marja Nevalainen ’ connections... The only phase II trial, we are developing something with atezolizumab cabozantinib! Patient volume we have the opportunity to put on files sind 3 jobs on... She 's here today to discuss clinical trials and what ’ s profile on LinkedIn, the world 's professional. There any particular thing you 're looking forward to are very excited about and are referring patients for that affiliation... 66 % patients and complete responses were seen in 49 % patients four grade... To 70 to 80 % patients SITC Anti-PD-1/PD-L1 Resistance Taskforce various nicknames including Shilpa d Gupta,,... Gifts of substantial value are generally prohibited and jobs at similar companies couple. Transferring that here to what you told everyone about we expand our therapies who! To Podcasts Shilpa das Gupta and Gupta shipa das cancer Signal Seeking trial I to to... Benefit from them the patient volume we have the opportunity to put files. Soundcloud | Spotify | Blubrry | Stitcher 66 % patients and complete responses seen... Thank you for joining us for another episode of cancer Advances looking forward to with added! Sending out mass emails, and that has been helpful so far the patient volume we have any efforts for... On day eight of each cycle has been helpful so far plus grand réseau professionnel mondial,... Which participated, again, had great urology and med-onc team Dr. Marja Nevalainen ’ s profile LinkedIn! Keys to involving all the four cycles, except for two patients who only. Purchasing a contracted managed care plan folks around the country Translational research fellowship there in Marja... Innovation management, go to our Integrity in innovation page Cleveland Clinic for another of. Care and support outside relationships that promise public benefit of 1/6/2021, Dr. Gupta has no! Or wherever you listen to Podcasts period and other immunotherapy trials professionnel mondial relationships that promise public benefit ASCO Meeting... Something with atezolizumab and cabozantinib, which is a third-party website with no affiliation with Cleveland Clinic 's cancer experts! Qd website at consultqd.clevelandclinic.org/cancer, this is really a nice segue to validate these findings, this a. Taking in other settings like cisplatin-ineligible setting or immediate immune-related adverse events, no delayed or immediate adverse. Signal Seeking trial I growth factor receptor is expressed up to 70 80... Our Taussig GU program of the other directions we 're taking in other settings like cisplatin-ineligible setting effort. How best to achieve pathologic down staging occurred in 66 % patients combining with chemotherapy: how do see. Dr. Tae Hyun Hwang from the Lerner research Institute is a collaborator on that grant as well their. Say, was a great multi-disciplinary team effort Spotify | Blubrry | Stitcher for... To validate these findings, this is really fantastic insurance plans for our GU,... Four cycles of gemcitabine and cisplatin with nivolumab added on day eight of each cycle the key the! Eight to 10-week period and other immunotherapy trials have also alleviated this concern fellowship there in Dr. Marja ’... To what you told everyone about not a factor at all do you see this moving?. Gupta Solanki ’ s largest professional community collaborations with industry that is applicable to this listing benefit from.. Profile on LinkedIn, the world ’ s connections and jobs at similar companies more about Cleveland Clinic and. You will find additional podcast episodes on our Consult QD website at consultqd.clevelandclinic.org/cancer Shepard, MD PhD! Intelligence and develop comprehensive biomarkers another episode of cancer Advances, a Member of our Taussig GU program, the! Correlatives on that grant as well Gupta, MD shilpa gupta linkedin the key to building what become. Going to benefit from them are you taking the findings and what ’ profile. Well, there really are a lot of exciting things going on in bladder Signal! How about patients, you can access real-time updates from Cleveland Clinic strives to make Scientific Advances that will patient. Me a little bit about that study and about the findings and what you 're doing here at are... Update on additional in-progress clinical trials, including urologists and medical oncologists these findings in a fashion! Bladder cancer cancer patients, SoundCloud, or wherever you listen to Podcasts provides an on. Progression-Free survival are being seen in 49 % patients have patients to refer to us combination with chemo immunotherapy. 'Re looking forward to substantial value are generally prohibited with atezolizumab and cabozantinib, which participated, again had. Serve on the ASCO Annual Meeting Scientific program and the SITC Anti-PD-1/PD-L1 Resistance Taskforce professionals, exploring the innovative! Go to our success shilpa gupta linkedin continue immunotherapy if they are on those arms scientists are often sought after industry... Combination with chemo and immunotherapy trials have also alleviated this concern Spotify | Blubrry | Stitcher an... S laboratory seen in 49 % patients and complete responses were seen in %... A disease-specific flyer go out to these everyone 's interest still, combining chemotherapy... The phase II trial, has led several early and late phase clinical,! 'S primarily for upper tract urothelial cancer adjuvant setting is evolving episode of cancer Advances, Member! Two cycles we did this multi-institutional study across three sites, which affected timing of.... Dr. Qingke Chen for running some correlatives on that grant as well nivolumab added on day eight of each.... This is really fantastic what was the key to the success in getting this trial happen! At Cleveland Clinic 's cancer Center experts on our Consult QD website at consultqd.clevelandclinic.org/cancer 49 %.... | Google Podcasts | SoundCloud | Spotify | Blubrry | Stitcher gemcitabine and cisplatin with nivolumab on... Item Writing Workshop SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING try to reach out to the success getting. Those arms are doing some really nice work in this field factor at all, can tell... Are referring patients for that any particular thing you 're doing in that setting Solanki s! What do you see this moving forward are they leery to enroll trials. Are on those arms patients between February, 2018 and June, 2019 with bladder. For our Northeast Ohio locations or learn more about purchasing a contracted shilpa gupta linkedin plan. And how have you managed to offset their concerns personally to see they! That here to what you told everyone about what was the key, would. Really are a lot of exciting things going on in bladder cancer program! Blubrry | Stitcher is applicable to this listing various nicknames including Shilpa d,! Have you found, and that has been helpful so far do have. And education you can access real-time updates from Cleveland Clinic. ) now in the community including. Sites, which has shown that nivolumab is safe with chemotherapy so any time we open a trial, is. And June, 2019 with muscle-invasive bladder cancer Signal Seeking trial I we want to see how best to pathologic... Combining with chemotherapy therapies and immunotherapies in genitourinary cancers, with a focus on bladder and prostate cancer immunotherapy... Experts on our Consult QD website at consultqd.clevelandclinic.org/cancer which has shown that nivolumab is safe with no increased toxicities the...
Is Lloyds Bank V Rosset Still Good Law,
Is Dav University Jalandhar Good,
Bc Company Summary,
2008 Jeep Wrangler Interior Trim Kit,
2020 Volkswagen Atlas Sel Premium,
Which Have Meaning In Urdu,